Cell MedX Corp (CMXC)
| Market Cap | 6.68M |
| Revenue (ttm) | 2,340 |
| Net Income (ttm) | -876,108 |
| Shares Out | 62.92M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,991 |
| Open | 0.107 |
| Previous Close | 0.107 |
| Day's Range | 0.106 - 0.113 |
| 52-Week Range | 0.100 - 0.318 |
| Beta | 0.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CMXC
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre...
News
Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director
Carson City, Nevada--(Newsfile Corp. - April 27, 2022) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of t...
Cell MedX Corp. to Attend the 29th Annual Wellness Show 2022 Held in Vancouver, BC
Carson City, Nevada--(Newsfile Corp. - March 24, 2022) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of t...